Skip to main content
. 2019 Feb 19;12:31. doi: 10.3389/fnmol.2019.00031

FIGURE 5.

FIGURE 5

Combined treatment with anti miR-124 and -137 AMOs partially restores non-convulsive seizure-induced alterations in proliferation and NSC identity 3 days post SE onset. (A) Expression levels of miR-124 72 h post ncSZ and following AMO administration. (B) Expression levels of miR-137 72 h after ncSZ and following AMO administration. (C) Expression levels of the unrelated miR-19a 72 h after ncSZ, and following AMO administration. (D–F) combined AMO treatment successfully rescued the ncSZ-induced neuroblast proliferation, while not altering proliferation levels in Type A NSCs and NPCs. (G) The loss of Type A NSCs was rescued by the administration of the combined AMOs (Sal + NT vs. KA + AMOs, ns). (H) The decrease in the relative proportion of Type B NSCs among the NSC pool was also rescued by the AMO treatment (Sal + NT vs. KA + AMO, ns; KA + NT vs. KA + AMO, P < 0.05). (I) The induction of rNSCs upon ncSZ was not rescued by the AMO treatment; however, (J) as the number of Type A NSCs was restored, the rNSC/Type A NSC ratio was partially restored (Sal + NT vs. KA + AMO, ns). (K) Administration of individual AMOs 2 h post ncSZ partially prevents the loss of Type A NSCs. (L) Administration of individual AMOs 2 h post ncSZ did not prevent the loss of Type B NSCs. ∗P < 0.05.